Cardiomyopathy Trial, Recruiting NCT05491655 Sponsor: Miulli General Hospital Condition: Cardiomyopathy
Back to Cardiomyopathy

Cardiomyopathy Trial, Recruiting

NCT05491655
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People whose heart is pumping at less than 50% of its normal capacity (as measured by a heart function test called ejection fraction)
  • People whose ejection fraction is between 36–50% and who also have elevated levels of certain heart stress markers in their blood (called BNP or NT-proBNP), and for whom a doctor has determined that an implantable heart device (ICD) is medically appropriate
  • People with heart failure symptoms ranging from none to severe, as classified by a standard medical scale (NYHA class I–IV)
  • People with a normal or near-normal electrical signal timing in their heart, measured as 110 milliseconds or less on a heart tracing test (ECG)

Who may not be able to join:

  • People who have another serious illness where life expectancy is estimated to be less than one year
  • People who are not able to give informed consent to participate in a study
  • People who are pregnant
  • People who have previously had surgery on their aortic heart valve

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0803054219

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Miulli General Hospital
Registry
ClinicalTrials.gov
Start date
29 March 2023
Est. completion
1 February 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Change in left ventricular ejection fraction

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov